In Endo, Vernalis Finds a Believer in Frova

Sep 01 2004

Listen to this article

Endo Pharmaceuticals licenses US rights to Vernalis' migraine drug Frova. The specialty pharma firm feels it can differentiate Frova from significant competition in the triptan market through its specialist-focused marketing approach and by extending Frova's label to include prevention of menstrually associated migraine.

Vernalis PLC 's management hasn't had much time to rest this summer. In June, it signed a deal with Biogen Idec Inc. for the UK firm's Phase I Parkinson's disease treatment V2006 and in mid-August the company announced that Novartis AG 's Novartis Institutes for Biomedical Research would exercise its option on Vernalis' preclinical cancer program targeting Hsp90. [See Deal][See Deal] But the summer's most prominent objective for the Vernalis team was re-licensing its marketed frovatriptan (Frova) migraine product.

When Vernalis reacquired North American rights to Frova in March 2004 from Elan Corp. PLC , Vernalis CEO Simon...

More from In Vivo Archive

In Partnership with Cerba Research
Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
New Identifying The Barriers For Use Of Digital Clinical Trial Technologies
Apr 03 2024
Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.
Nesw Fewer Acquisitions And Alliances In 2023, But Valuations Increased
Apr 03 2024
• By Joseph Haas
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Publisher’s Spotlight: Citeline News And Insights App
Mar 04 2024
• By In Vivo Team
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from In Vivo

Vigya test infogram
Jul 15 2026
add a desc test
Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future
Jul 15 2026
• By Edwin Elmhirst and Lucie Ellis-Taitt
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone
Jul 09 2026
• By Edwin Elmhirst and Lucie Ellis-Taitt
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.